The European Union (EU) says it will advance a grant of 32 million euros to support the development of vaccine manufacturing and the pharmaceutical industry in Ghana.
Under the EU initiative on the Manufacturing and Access to Vaccines, Medicines and Health Technologies (MAV+), which was initiated in 2021, part of the grant will be used to finance the construction of a vaccine manufac¬turing plant in Ghana.
According to the Ghanaian Times report on Thursday, an agreement for the release of the grant was signed between Ghana and EU in Accra yesterday as part of the Ghana-EU Business Forum programme.
The report noted that the second Ghana-EU Business Forum, a two-day programme, which opened in Accra yester¬day was on the theme “Fostering Investment in Non-Traditional Value Chains under the EU Global Gateway Strategy.”
It recalled that the Global Gateway programme was initiated by the EU to invest about 300 million euros between 2021 and 2027 to foster economic growth in Africa.
The Presidential Advisor on Health, Dr Anthony Nsiah-Asare, signed the grant agreement on be¬half of the government of Ghana, while the Deputy Director General of the European Commission, Madam Myriam Ferran signed on behalf of the EU.
Ms Ferran in her remarks said “European Union is committed to supporting Ghana’s development goals, and this investment in vac¬cine manufacturing and pharma¬ceutical industry is a testament to the partnership between Ghana and EU.”
She said the programme would not only enhance Ghana’s health¬care sector but also contribute to the growth of the country’s economy.
“We are working together with the EU from the beginning of the President’s vision to make Ghana become a regional vaccine manu¬facturing hub,” Dr Nsiah-Asare, said,
He said the objective of govern¬ment was to make Ghana the hub for the manufacture of vaccines in Africa and lauded the EU for the support.
GIK/APA
EU supports Ghana’s pharmaceutical industry with €32m development grant
